<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647175</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-102-19</org_study_id>
    <nct_id>NCT04647175</nct_id>
  </id_info>
  <brief_title>Aronia in the Type 2 Diabetes Treatment Regimen</brief_title>
  <official_title>Aronia in the Type 2 Diabetes Treatment Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a triple-crossover study, the effect aronia consumption on type 2 diabetes will be&#xD;
      examined. 48 type 2 diabetes patients need to complete the trial. Each patient will receive&#xD;
      two daily doses of both fermented aronia, aronia, or placebo for eight weeks each. There will&#xD;
      be 3 weeks wash-out periods between the intervention periods. Before and after the&#xD;
      intervention periods, various measurements will be performed to assess the effects of aronia,&#xD;
      fermented aronia, and placebo on type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Fermented aronia extract (FAE) improves glycaemia and lipidaemia in T2D more&#xD;
      efficiently than both non-fermented aronia extract (NFAE) and placebo.&#xD;
&#xD;
      Research questions:&#xD;
&#xD;
      Does FAE/NFAE when administered to T2D subjects:&#xD;
&#xD;
        -  Improve glucose responses to an oral glucose tolerance test and HbA1C?&#xD;
&#xD;
        -  Improve fasting LDL-, HDL- and total cholesterol?&#xD;
&#xD;
        -  Reduce insulin resistance and increase total antioxidative/anti-inflammatory capacity?&#xD;
&#xD;
        -  Increase circulating GLP-1 and GIP levels with lower DPP4 activity?&#xD;
&#xD;
        -  Alleviate hypertension and obesity?&#xD;
&#xD;
      Methods A total of 48 T2D patients is needed for the double blind, randomized triple&#xD;
      cross-over trial. The patients will consume FAE, NFAE or placebo daily divided into two doses&#xD;
      which is expected to provide a sufficient dose of bioactive phenolic compounds. The patients&#xD;
      will be recruited through &quot;forsoegsperson.dk&quot;, &quot;sundhed.dk&quot;, and flyers placed at Aarhus&#xD;
      university hospital (AUH). T2D patients with fasting blood glucose ≤ 12 mM and HbA1c &gt; 6.1%&#xD;
      and &lt; 10%, without severe comorbidities, will be included. Before enrolment, the patients&#xD;
      receive all necessary study information (written and oral) including potential adverse&#xD;
      effects (e.g. aronia allergy), and they will have to provide their informed consent (visit&#xD;
      1). There will be an assessment of whether the patients fulfill the criteria as well.&#xD;
&#xD;
      The randomized double-blinded triple cross-over study consists of three eight weeks&#xD;
      intervention periods (placebo, FAE and NFAE), where the participants are randomly assigned to&#xD;
      the order of treatments (six different possibilities of order). The intervention periods are&#xD;
      separated by minimum three weeks wash-out periods (see figure 1 for details). Before and&#xD;
      after each intervention period, i.e. six times, oral glucose tolerance tests (OGTT) will be&#xD;
      performed. The Central Denmark Region Committees on Health Research Ethics has approved the&#xD;
      trial.&#xD;
&#xD;
      Analyses OGTT: Prior to the OGTT, the participants have fasted for 8 hours where after they&#xD;
      will consume 75 g glucose dissolved in 300 ml water within 5 minutes. Blood will be sampled&#xD;
      at time points -10, 0, 30, 60, 90, 120, and 240 minutes.&#xD;
&#xD;
      Blood Analyses: After the blood sampling, plasma will be stored at -80° C until further&#xD;
      analysis. Obviously, the investigators aim to determine if FAE and NFAE consumption is&#xD;
      capable of lowering the fasting and postprandial blood sugar and thus, the levels of glucose,&#xD;
      fructosamin and HbA1c will be measured. The concentration of advanced glycosylation end&#xD;
      products will be assessed in fasted blood samples. Also, lipidaemia will be examined, e.g.&#xD;
      total cholesterol, triglyceride, high-density lipoprotein and low-density lipoprotein&#xD;
      concentrations. The inflammatory state will be assessed by measuring the level of pro- and&#xD;
      anti-inflammatory cytokines as well as the concentration of C-reactive protein in fasting&#xD;
      blood samples. To determine whether aronia acts through incretin mediated regulation, the&#xD;
      concentrations of GIP and GLP-1 and the activity of DDP4 will be measured. The concentrations&#xD;
      of glucagon, insulin, and adiponectin will be assessed as well.&#xD;
&#xD;
      Insulin resistance: β-cell dysfunction and insulin resistance will be estimated from blood&#xD;
      glucose and insulin concentrations using Homeostasis Model Assessment (3) and Matsuda Index&#xD;
      (4) which are based on concentrations measured at fasting states and during the OGTT,&#xD;
      respectively.&#xD;
&#xD;
      Diurnal blood pressure: 24-hour ambulatory blood pressure monitoring will be carried out. The&#xD;
      necessary equipment is available at AUH. The participants will have their 24-hour blood&#xD;
      pressure measured before and after each intervention period.&#xD;
&#xD;
      Body mass index (BMI): At the first visit the participants height and weight are measured,&#xD;
      and the weight will subsequently be monitored.&#xD;
&#xD;
      Metabolomics and microbiomics assays: The results from the previous tests (effects on main&#xD;
      outcomes) will determine the extent of the subsequent metabolomics and microbiomics analyses.&#xD;
      Fecal samples for microbiomics, as well as blood and urine samples for metabolomics will be&#xD;
      stored at -80° C until use.&#xD;
&#xD;
      Data analysis: The power calculation is based on our primary effect parameter glucose&#xD;
      incremental area under the curve (iAUC). The number of participants needed to obtain a&#xD;
      statistical power of 80% at a level of P&lt;0.05 (α=0.05; 1-β=0.8) was calculated as 48. The&#xD;
      investigators wanted to detect a minimal relevant difference for the area of (mean ± s.d.)&#xD;
      65±50 mmol/l x 120 min, which gives us an estimated effect size of 1.30. The anticipated&#xD;
      dropout is 20%. ANOVA will be conducted for each variable to determine if the variables&#xD;
      change upon administration of FAE, NFAE, or placebo as well as to assess intergroup&#xD;
      variability at baseline and endpoint. Significance will be set to p &lt; 0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 23, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose incremental area under the curve (iAUC)</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured during the OGTTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood glucose total area under the curve (tAUC)</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured during the OGTTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood and urin, fasting + during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting + during OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamin</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and oxidative markers</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incretins</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DPP4 activity</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advanced glycation end products</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in blood and urin, fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiomics</measure>
    <time_frame>Throughout the study (up to 1 year)</time_frame>
    <description>Measured in feces</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Fermented aronia - aronia - placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants receive each intervention for 8 weeks in the stated order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fermented aronia - placebo - aronia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants receive each intervention for 8 weeks in the stated order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - aronia - fermented aronia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants receive each intervention for 8 weeks in the stated order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - fermented aronia - aronia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants receive each intervention for 8 weeks in the stated order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aronia - placebo - fermented aronia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants receive each intervention for 8 weeks in the stated order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aronia - fermented aronia - placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants receive each intervention for 8 weeks in the stated order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fermented aronia</intervention_name>
    <description>Given twice daily for 8 weeks</description>
    <arm_group_label>Aronia - fermented aronia - placebo</arm_group_label>
    <arm_group_label>Aronia - placebo - fermented aronia</arm_group_label>
    <arm_group_label>Fermented aronia - aronia - placebo</arm_group_label>
    <arm_group_label>Fermented aronia - placebo - aronia</arm_group_label>
    <arm_group_label>Placebo - aronia - fermented aronia</arm_group_label>
    <arm_group_label>Placebo - fermented aronia - aronia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aronia</intervention_name>
    <description>Given twice daily for 8 weeks</description>
    <arm_group_label>Aronia - fermented aronia - placebo</arm_group_label>
    <arm_group_label>Aronia - placebo - fermented aronia</arm_group_label>
    <arm_group_label>Fermented aronia - aronia - placebo</arm_group_label>
    <arm_group_label>Fermented aronia - placebo - aronia</arm_group_label>
    <arm_group_label>Placebo - aronia - fermented aronia</arm_group_label>
    <arm_group_label>Placebo - fermented aronia - aronia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given twice daily for 8 weeks</description>
    <arm_group_label>Aronia - fermented aronia - placebo</arm_group_label>
    <arm_group_label>Aronia - placebo - fermented aronia</arm_group_label>
    <arm_group_label>Fermented aronia - aronia - placebo</arm_group_label>
    <arm_group_label>Fermented aronia - placebo - aronia</arm_group_label>
    <arm_group_label>Placebo - aronia - fermented aronia</arm_group_label>
    <arm_group_label>Placebo - fermented aronia - aronia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  ≥30 ≤80 years of age&#xD;
&#xD;
          -  Fasting blood glucose ≤12 mmol/liter.&#xD;
&#xD;
          -  HbA1c &gt; 6,1% og &lt;10%(&gt;43 og &lt; 86 mmol/mol) if patients are in medical diabetes&#xD;
             treatment&#xD;
&#xD;
          -  HbA1c &gt; 6,5% og &lt;10% (&gt;48 og &lt; 86 mmol/mol) if patients are not in medical diabetes&#xD;
             treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Changes in diabetes within the last 3 months.&#xD;
&#xD;
          -  Serious comorbidities, including cardiovascular-, neurological-, psychological- and/or&#xD;
             renal diseases.&#xD;
&#xD;
          -  Pregnant or planned pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine B Christiansen, cand.scient.med.</last_name>
    <phone>004528518032</phone>
    <email>c.christiansen@clin.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Søren Gregersen, chief physician, PhD</last_name>
    <phone>004530134245</phone>
    <email>soeren.gregersen@aarhus.rm.dk</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aronia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

